{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:30Z","timestamp":1793410770054,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12072-023-10542-9","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:02:47Z","timestamp":1684987367000},"page":"882-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial"],"prefix":"10.1007","volume":"17","author":[{"given":"Alireza","family":"Ramandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Merat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sharafkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Radmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Nateghi Baygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Delavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-3628","authenticated-orcid":false,"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"7","key":"10542_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1","journal-title":"Gastroenterology"},{"key":"10542_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med (Lausanne). 2021;8: 693507","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10542_CR3","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082\u20132089","journal-title":"Liver Int"},{"issue":"2","key":"10542_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389\u201397.e10","journal-title":"Gastroenterology"},{"issue":"10","key":"10542_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1080\/00365520903171284","volume":"44","author":"S Dam-Larsen","year":"2009","unstructured":"Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44(10):1236\u20131243","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10542_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franz\u00e9n LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865\u2013873","journal-title":"Hepatology"},{"issue":"1","key":"10542_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"2","key":"10542_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","volume":"7","author":"N Rafiq","year":"2009","unstructured":"Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234\u2013238","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10542_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hep.23314","volume":"51","author":"C S\u00f6derberg","year":"2010","unstructured":"S\u00f6derberg C, St\u00e5l P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595\u2013602","journal-title":"Hepatology"},{"issue":"12","key":"10542_CR10","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","volume":"54","author":"G Targher","year":"2005","unstructured":"Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541\u20133546","journal-title":"Diabetes"},{"issue":"21","key":"10542_CR11","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/eurheartj\/ehab919","volume":"43","author":"S Merat","year":"2022","unstructured":"Merat S, Jafari E, Radmard AR, Khoshnia M, Sharafkhah M, Nateghi Baygi A, et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur Heart J. 2022;43(21):2023\u20132033","journal-title":"Eur Heart J"},{"issue":"4","key":"10542_CR12","first-page":"Cd009868","volume":"4","author":"AN de Cates","year":"2014","unstructured":"de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;4(4):Cd009868","journal-title":"Cochrane Database Syst Rev"},{"key":"10542_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.880054","volume":"9","author":"OA Kandil","year":"2022","unstructured":"Kandil OA, Motawea KR, Aboelenein MM, Shah J. Polypills for primary prevention of cardiovascular disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9: 880054","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10542_CR14","first-page":"515","volume":"18","author":"S Merat","year":"2015","unstructured":"Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an Urban Iranian population with special focus on nonalcoholic steatohepatitis: A pragmatic randomized controlled trial within a cohort (PolyIran\u2014liver)\u2014study protocol. Arch Iran Med. 2015;18(8):515\u2013523","journal-title":"Arch Iran Med"},{"issue":"1","key":"10542_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/jch.13162","volume":"20","author":"JR Nansseu","year":"2018","unstructured":"Nansseu JR, Tankeu AT, Kamtchum-Tatuene J, Noubiap JJ. Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges. J Clin Hypertens (Greenwich). 2018;20(1):168\u2013173","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10199","key":"10542_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","volume":"394","author":"G Roshandel","year":"2019","unstructured":"Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672\u2013683","journal-title":"Lancet"},{"issue":"5","key":"10542_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11886-017-0853-y","volume":"19","author":"A Roy","year":"2017","unstructured":"Roy A, Naik N, Srinath RK. Strengths and limitations of using the polypill in cardiovascular prevention. Curr Cardiol Rep. 2017;19(5):45","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10542_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/ije\/dyp161","volume":"39","author":"A Pourshams","year":"2010","unstructured":"Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort profile: the Golestan cohort study\u2013a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010;39(1):52\u201359","journal-title":"Int J Epidemiol"},{"issue":"10","key":"10542_CR19","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD Predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67(10):4919\u20134928","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10542_CR20","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138\u201347.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10542_CR21","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","volume":"15","author":"HH Liu","year":"2021","unstructured":"Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337\u20131346","journal-title":"Hepatol Int"},{"key":"10542_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154779","volume":"120","author":"S Liu","year":"2021","unstructured":"Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120: 154779","journal-title":"Metabolism"},{"issue":"9","key":"10542_CR23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.5551\/jat.Er19356","volume":"23","author":"K Nishimura","year":"2016","unstructured":"Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the Suita study. J Atheroscler Thromb. 2016;23(9):1138\u20131139","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"10542_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115\u20131128","journal-title":"Hepatol Res"},{"issue":"13","key":"10542_CR25","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","volume":"134","author":"HJ Zhang","year":"2021","unstructured":"Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999\u20132016. Chin Med J (Engl). 2021;134(13):1593\u20131601","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"10542_CR26","volume":"6","author":"A Rodgers","year":"2011","unstructured":"Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, et al. An international randomised placebo-controlled trial of a four-component combination pill (\u201cpolypill\u201d) in people with raised cardiovascular risk. PLoS\u00a0One. 2011;6(5): e19857","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"10542_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041297","volume":"7","author":"DS Wald","year":"2012","unstructured":"Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS\u00a0One. 2012;7(7): e41297","journal-title":"PLoS\u00a0One"},{"issue":"7404","key":"10542_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","volume":"326","author":"NJ Wald","year":"2003","unstructured":"Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419","journal-title":"BMJ"},{"issue":"2","key":"10542_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2013.1113","volume":"11","author":"SJ Rolnick","year":"2013","unstructured":"Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54\u201365","journal-title":"Clin Med Res"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10542-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T14:35:34Z","timestamp":1690641334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10542-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10542"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10542-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alireza Ramandi, Jacob George, Shahin Merat, Elham Jafari, Maryam Sharafkhah, Amir Reza Radmard, Alireza Nateghi Baygi, Alireza Delavari, Zahra Mohammadi, Hossein Poustchi and  Reza Malekzadeh  declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}